Integra LifeSciences Holdings (IART)
Receivables turnover
| Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | ||
|---|---|---|---|---|---|---|
| Revenue | US$ in thousands | 1,608,880 | 1,486,360 | 1,506,670 | 1,533,950 | 1,298,690 |
| Receivables | US$ in thousands | 272,370 | 259,327 | 263,465 | 231,831 | 225,532 |
| Receivables turnover | 5.91 | 5.73 | 5.72 | 6.62 | 5.76 |
December 31, 2024 calculation
Receivables turnover = Revenue ÷ Receivables
= $1,608,880K ÷ $272,370K
= 5.91
The receivables turnover ratio for Integra LifeSciences Holdings has shown variations over the past five years. The ratio stood at 5.76 in December 31, 2020, increased to 6.62 by December 31, 2021, but decreased slightly to 5.72 by December 31, 2022. It then remained relatively stable around 5.7 to 5.9 for the subsequent years up to December 31, 2024.
Overall, the trend indicates that Integra LifeSciences has been efficient in collecting its accounts receivable, as a higher turnover ratio implies the company is collecting payments more frequently during the year. However, the slight fluctuations in the ratio may suggest potential changes in the company's credit policies, customer payment behavior, or sales volume that could have impacted its receivables turnover performance. Further analysis of the company's receivables management practices and industry comparisons may provide deeper insights into the effectiveness of Integra LifeSciences' credit and collection policies.
Peer comparison
Dec 31, 2024